In early trading on the 27th, ROKIT Healthcare is surging more than 14%. Buying is seen as gathering on news that it registered a patent for technology that solves the challenge of "blood clot formation" in artificial organ transplants.
As of 10:22 a.m. on the 27th, ROKIT Healthcare on the KOSDAQ market is trading at 71,900 won, up 9,300 won (14.86%) from the previous trading day.
ROKIT Healthcare said on the 27th that it registered a patent for a "next-generation decellularization and recellularization core technology" that prevents blood clot formation. ROKIT Healthcare is an artificial intelligence (AI)-based organ regeneration platform company.
The newly registered patent applies a special process to an organ from which cells have been removed to prevent blood clot formation, and then implants the patient's customized cells again through a recellularization technique.
It improves damage to the inner walls of blood vessels and immune rejection, which are limitations in artificial organ research, and is cited as a technology that can maximize transplant success rates.